Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Anti-integrin antibodies

7 evidence topics · 6 sources

Recommendations and meta-analysis for vedolizumab: ECCO 2026 guideline

“We recommend treatment with vedolizumab for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, low certainty of evidence] [Agreement: 100%]” (opens the source at this quote in a new tab)

“We recommend vedolizumab for the maintenance of remission in patients with ulcerative colitis who responded to induction therapy with vedolizumab [strong recommendation, moderate certainty of evidence] [Agreement: 100%]” (opens the source at this quote in a new tab)

“We suggest the use of vedolizumab rather than adalimumab for the induction and maintenance of remission in moderate-to-severe ulcerative colitis [weak recommendation, low certainty of evidence] [Agreement: 100%]” (opens the source at this quote in a new tab)

“Induction responders who subsequently received vedolizumab were more likely to achieve clinical remission than those receiving placebo after 52–60 weeks of follow-up [RR: 2.37; 95% CI: 1.74–3.23].” (opens the source at this quote in a new tab)

“Rates of SAEs in patients treated with vedolizumab were not significantly different from those receiving placebo [RR: 0.71; 95% CI: 0.39–1.30].” (opens the source at this quote in a new tab)

“In the subgroup analysis, the results were statistically significant in biologic-naive patients and only numerically superior in the biologic-exposed population.” (opens the source at this quote in a new tab)